Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- NUVB
- Price
- 5.91
- Stock movement down
- -0.24 (-3.90%)
- Company name
- Nuvation Bio Inc
- Exchange
- (NYSE ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.02B
- Ent value
- 2.20B
- Price/Sales
- 75.53
- Price/Book
- 6.20
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- 129.07%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
NUVB does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 75.53 |
| Price to Book | 6.20 |
| EV to Sales | 82.14 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 341.83M |
| EPS (TTM) | -0.64 |
| FCF per share (TTM) | -0.56 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 26.75M |
| Gross profit (TTM) | 14.51M |
| Operating income (TTM) | -232.97M |
| Net income (TTM) | -217.48M |
| EPS (TTM) | -0.64 |
| EPS (1y forward) | -0.28 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 54.26% |
| Operating margin (TTM) | -870.98% |
| Profit margin (TTM) | -813.07% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 98.90M |
| Net receivables | 13.85M |
| Total current assets | 577.53M |
| Goodwill | 0.00 |
| Intangible assets | 11.68M |
| Property, plant and equipment | 6.00M |
| Total assets | 601.56M |
| Accounts payable | 15.36M |
| Short/Current long term debt | 57.55M |
| Total current liabilities | 68.13M |
| Total liabilities | 275.68M |
| Shareholder's equity | 325.88M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -190.00M |
| Capital expenditures (TTM) | 278.00K |
| Free cash flow (TTM) | -190.27M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -66.74% |
| Return on Assets | -36.15% |
| Return on Invested Capital | -57.16% |
| Cash Return on Invested Capital | -50.01% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 6.22 |
| Daily high | 6.25 |
| Daily low | 5.86 |
| Daily Volume | 8.75M |
| All-time high | 14.57 |
| 1y analyst estimate | 11.25 |
| Beta | 1.59 |
| EPS (TTM) | -0.64 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 5 Mar 2026 |
Downside potential
Loading...
Downside potential data
| NUVB | S&P500 | |
| Current price drop from All-time high | -59.44% | -0.89% |
| Highest price drop | -88.61% | -19.00% |
| Date of highest drop | 8 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -76.80% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
2.02B
Marketcap category
Mid-cap
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.
Employees
291
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page